HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.

HIMS), recently made an interesting announcement. The healthcare company said that it will now offer branded Zepbound, Eli Lilly’s (NYSE: LLY) blockbuster weight loss drug. Zepbound is the most ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Personally, I've been on Zepbound for nearly 10 weeks now and I ... professional online is available in some states through Hims and Hers for men and women. Struggling with spring allergies?

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

Hims & Hers Health HIMS, recently made an interesting announcement. The healthcare company said that it will now offer branded Zepbound, Eli Lilly’s LLY blockbuster weight loss drug. Zepbound is ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.